Characteristics | Subgroups | P Value | |
---|---|---|---|
TNF-α ≤ 8.1 pg/mL | TNF-α > 8.1 pg/mL | ||
Patients numbers | 49 | 98 | |
Cytokines–biopsy time intervala (months) | 25.93 (5.27–55.90) | 28.55 (7.14–67.47) | 0.63 |
Mean age (yr) | 33 (28–41) | 40 (29–47) | 0.03 |
Male, n (%) | 18 (36.7) | 53 (54.1) | 0.047 |
Systolic BP (mmHg) | 120 (110–120) | 120 (118–130) | 0.001 |
Diastolic BP (mmHg) | 70 (60–80) | 80 (70–80) | 0.02 |
Mean arterial pressure (mmHg) | 87 (78–93) | 93 (87–97) | 0.003 |
Urinary red blood cell (/μL) | 34 (7–131) | 22 (7–67) | 0.13 |
Urinary protein to serum creatinine ratio (mg/g Cr) | 486 (159–881) | 756 (335–1596) | 0.009 |
24-h urine protein excretion (g/24 h) | 0.68 (0.30–1.09) | 0.99 (0.40–1.70) | 0.03 |
< 0.3 | 12 (24.5%) | 15 (15.3%) | 0.009 |
0.3–0.99 | 23 (46.9%) | 36 (36.7%) | |
1.0–2.99 | 13 (26.5%) | 33 (33.7%) | |
≥ 3 | 1 (2.0%) | 14 (14.3%) | |
Serum creatinine (mg/dL) | 0.89 (0.72–1.07) | 1.19 (0.92–1.52) | < 0.0001 |
Cystatin C (mg/dL) | 0.98 (0.79–1.12) | 1.22 (1.00–2.00) | < 0.0001 |
eGFR (mL/min•1.73m2)b | 92.95 (73.96–118.78) | 70.94 (52.26–91.57) | < 0.0001 |
CKD Stagesc, n (%) | < 0.0001 | ||
1 | 30 (61.2) | 27 (27.6) | |
2 | 15 (30.6) | 34 (34.7) | |
3a | 2 (4.1) | 20 (20.4) | |
3b | 1 (2.0) | 7 (7.1) | |
4 | 1 (2.0) | 4 (4.1) | |
5 | 0 (0.0) | 6 (6.1) | |
Oxford classificationd, n (%) | |||
M0/ M1 | 9 (18.4), 40 (81.6) | 7 (7.1),91 (92.9) | 0.04 |
E0/E1 | 38 (77.6), 11 (22.4) | 75 (76.5), 23 (23.5) | 0.89 |
S0/S1 | 13 (26.5), 36 (73.5) | 11 (11.2), 87 (88.8) | 0.02 |
T0/T1/T2 | 22 (44.9), 19 (38.8), 8 (16.3) | 23 (23.5), 46 (46.9), 29 (29.6) | 0.008 |
C0/C1/C2 | 22 (44.9), 23 (46.9), 4 (8.2) | 44 (44.9), 43 (43.9), 11 (11.2) | 0.79 |
Medical treatments, n (%) | |||
Untreated | 10 (20.4) | 25 (25.5) | 0.49 |
Corticosteroids | 22 (44.9) | 49 (50.0) | 0.56 |
Immunosuppressants | 26 (53.1) | 50 (51.0) | 0.82 |
ACE-Is/ARBs | 34 (69.4) | 65 (66.3) | 0.71 |